ORCID Profile
0000-0001-6394-658X
Current Organisations
University of Jordan
,
Instituto Politécnico de Lisboa Escola Superior de Tecnologia da Saúde de Lisboa
,
CISA - Centro de Investigação em Saúde de Angola
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Related Links
Publications
Efficacy and safety of pharmacological interventions for managing sickle cell disease in children and adolescents: protocol for a systematic review with network meta-analysis
Publisher: BMJ
Date: 02-2023
DOI: 10.1136/BMJOPEN-2022-064872
Abstract: Sickle cell disease (SCD), an inherited haemoglobinopathy, has important impact on morbidity and mortality, especially in paediatrics. Previous systematic reviews are limited to adult patients or focused only on few therapies. We aim to synthesise the evidence on efficacy and safety of pharmacological interventions for managing SCD in children and adolescents. This systematic review protocol is available at Open Science Framework (doi:10.17605/OSF.IO/CWAE9). We will follow international recommendations on conduction and report of systematic reviews and meta-analyses. Searches will be conducted in PubMed, Scopus and Web of Science (no language nor time restrictions) (first pilot searches performed in May 2022). We will include randomised controlled trials comparing the effects of disease-modifying agents in patients with SCD under 18 years old. Outcomes of interest will include: vaso-occlusive crisis, haemoglobin levels, chest syndrome, stroke, overall survival and adverse events. We will provide a narrative synthesis of the findings, and whenever possible, results will be pooled by means of pairwise or Bayesian network meta-analyses with surface under the cumulative ranking curve analyses. Different statistical methods and models will be tested. Dichotomous outcomes will be reported as OR, risk ratio or HR, while continuous data will be reported as standard mean differences, both with 95% CI/credibility interval. The methodological quality of the trials will be evaluated using the Risk of Bias 2.0 tool, and the certainty of the evidence will be assessed with the Grading of Recommendations Assessment, Development and Evaluation approach. This study refers to a systematic review, so no ethics approval is necessary. We intent to publish our findings in international, peer-reviewed journal. Data will also be presented to peers in scientific events. Additionally, the results obtained in this study may contribute towards the update of therapeutic guidelines and for the development of health policies for SCD. CRD42022328471.
Main causes of death in Dande, Angola: results from Verbal Autopsies of deaths occurring during 2009–2012
Publisher: Springer Science and Business Media LLC
Date: 04-08-2016
Etiology of Diarrhea in Children Younger Than 5 Years Attending the Bengo General Hospital in Angola
Publisher: Ovid Technologies (Wolters Kluwer Health)
Date: 02-2016
The impact of using a mobile application to improve asthma patients’ adherence to medication in Jordan
Publisher: SAGE Publications
Date: 07-2021
DOI: 10.1177/14604582211042926
Abstract: The main aim of this study is to assess the effectiveness of using a developed asthma mobile application to enhance medication adherence in Jordan. Asthma patients visiting outpatient respiratory clinics and using inhalers were recruited. Patients were assigned into two groups: intervention and control. The intervention group was instructed to download and use the application. Asthma control was assessed using Asthma Control Test (ACT) at baseline and at follow-up of 3 months for both groups. A total of 171 patients (control, n = 83, and intervention, n = 88) participated in the study. After 3 months of usage, patients in the intervention group achieved a significant improvement in ACT score compared to control ( p-value .05), and reported a significant satisfaction of the application use. Therefore, the asthma mobile application is found as an effective tool to enhance medication adherence in asthma patients.
Efficacy and safety of pharmacological interventions for managing sickle cell disease complications in children and adolescents: Systematic review with network meta‐analysis
Publisher: Wiley
Date: 14-03-2023
DOI: 10.1002/PBC.30294
Abstract: This study aimed to synthesize the evidence on the effects of disease‐modifying agents for managing sickle cell disease (SCD) in children and adolescents by means of a systematic review with network meta‐analyses, surface under the cumulative ranking curve (SUCRA) and stochastic multicriteria acceptability analyses (SMAA) (CRD42022328471). Eightteen randomized controlled trials (hydroxyurea [ n = 7], l ‐arginine [ n = 3], antiplatelets [ n = 2], immunotherapy/monoclonal antibodies [ n = 2], sulfates [ n = 2], docosahexaenoic acid [ n = 1], niprisan [ n = 1]) were analyzed. SUCRA and SMAA demonstrated that hydroxyurea at higher doses (30 mg/kg/day) or at fixed doses (20 mg/kg/day) and immunotherapy/monoclonal antibodies are more effective for preventing vaso‐occlusive crisis (i.e., lower probabilities of incidence of this event 14, 25, and 30%, respectively), acute chest syndrome (probabilities ranging from 8 to 30%), and needing of transfusions (11–31%), while l ‐arginine (100–200 mg/kg) and placebo were more prone to these events. Therapies were overall considered safe however, antiplatelets and sulfates may lead to more severe adverse events. Although the evidence was graded as insufficient and weak, hydroxyurea remains the standard of care for this population, especially if a maximum tolerated dose schedule is considered.
Related Organisations
Keele University
Location: United Kingdom of Great Britain and Northern Ireland
Instituto Nacional De Medicina Legal Delegação Do Sul
Location: Portugal
Instituto Politécnico De Lisboa Escola Superior De Tecnologia Da Saúde De Lisboa
Location: Portugal
Related Funding Activities
No related grants have been discovered for Miguel Brito.